Alteration of immune response using pan DR-binding peptides
First Claim
1. A composition comprising a peptide capable of binding antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus, the peptide consisting of 2 D-amino acids and 11 L-amino acids, said peptide having the formula R1 --R2 --R3 --R4 --R5, proceeding from the amino-terminus to the carboxy-terminus, wherein:
- R1 is a D-amino acid followed by alanine or lysine;
R2 is selected from the group consisting of cyclohexylalanine, tyrosine, and phenylalanine;
R3 is 3 or 4 amino acids, wherein each amino acid is independently selected from the group consisting of alanine, isoleucine, serine, glutamic acid and valine;
R4 is selected from the group consisting of threonine-leucine-lysine, lysine-threonine, and tryptophan-threonine-leucine-lysine; and
R5 consists of 2 or 4 amino acids followed by a D-amino acid, wherein each of the 2 or 4 amino acids is independently selected from the group consisting of alanine, serine and valine.
5 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.
221 Citations
56 Claims
-
1. A composition comprising a peptide capable of binding antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus, the peptide consisting of 2 D-amino acids and 11 L-amino acids, said peptide having the formula R1 --R2 --R3 --R4 --R5, proceeding from the amino-terminus to the carboxy-terminus, wherein:
-
R1 is a D-amino acid followed by alanine or lysine; R2 is selected from the group consisting of cyclohexylalanine, tyrosine, and phenylalanine; R3 is 3 or 4 amino acids, wherein each amino acid is independently selected from the group consisting of alanine, isoleucine, serine, glutamic acid and valine; R4 is selected from the group consisting of threonine-leucine-lysine, lysine-threonine, and tryptophan-threonine-leucine-lysine; and R5 consists of 2 or 4 amino acids followed by a D-amino acid, wherein each of the 2 or 4 amino acids is independently selected from the group consisting of alanine, serine and valine. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
-
34. A peptide which binds more than one DR allele, the peptide consisting of the formula R1 --R2 --R3 --R4 --R5, proceeding from the amino-terminus to the carboxy-terminus, wherein:
-
R1 is a D- or an L-amino acid residue followed by alanine or lysine; R2 is selected from the group consisting of tyrosine, and phenylalanine; R3 is 3 or 4 amino acids, wherein each amino acid is independently selected from the group consisting of alanine, isoleucine, serine, glutamic acid, and valine; R4 is selected from the group consisting of threonine-leucine-lysine, lysine threonine, and tryptophan-threonine-leucine-lysine; and R5 consists of 2 or 4 amino acids followed by a D- or an L-amino acid residue, wherein each of the 2 or 4 amino acids is independently selected from the group consisting of alanine, serine and valine. - View Dependent Claims (35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)
-
Specification